Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|August 21, 2025
AI Is Already Aiding Clinical Practice Across the Cancer Care Continuum
Author(s)Kyle Doherty
Fact checked by: Chris Ryan
Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.
Advertisement
Advertisement
The use of artificial intelligence (AI) is rapidly expanding in oncologic clinical practice, with applications including expediting administrative tasks, risk-stratification testing, research, and assistance with interpreting pathology and imaging results.
Related to this article
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement